First Interstate Bank Nektar Therapeutics Transaction History

First Interstate Bank

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2018 Jan 31, 2019	SELL	$30.43 - $56.65 $11,563 - $21,527	-380 Closed	0 $0
Q3 2018 Nov 07, 2018	BUY	$46.46 - $68.49 $17,654 - $26,026	380 New	380 $23,000

126

109M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $259M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of First Interstate Bank, based on Form 13F filings with the SEC.

Stay updated on First Interstate Bank with notifications on news.